|drug2536||Placebo Vaccine Wiki||1.00|
|drug389||BCG Vaccine Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to treat hospitalized patients with moderate COVID-19.
Description: PCR will be done to evaluate the change in viral loadMeasure: Viral load Time: day 1, 4, 7, 14 and 21
Description: Time to wean off oxygen supplementationMeasure: Evolution of acute respiratory syndrome Time: 21 days
Description: WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)Measure: Change in Clinical Condition Time: 21 days
Description: Time to be discharged from hospitalMeasure: Hospital discharge Time: 21 days
Description: Evaluation of change in acute respiratory syndromeMeasure: Rate of mortality within 21-days Time: 21 days
Description: Evaluation of change in acute respiratory syndromeMeasure: Need of mechanical ventilation Time: 21 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports